78
Participants
Start Date
September 30, 2008
Primary Completion Date
March 31, 2009
Study Completion Date
December 31, 2009
AH110690 (18F) Injection
All subjects will receive an I.V. dose of \[18F\]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of \[18F\]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).
GE Healthcare, Oslo
Lead Sponsor
Collaborators (1)
i3 Statprobe
INDUSTRY
Medpace, Inc.
INDUSTRY
Hvidovre University Hospital
OTHER
GE Healthcare
INDUSTRY